Ovarian cancer, what is it and how is

Ovarian cancer, what is it and how is

Written by: Dr. Juan José Torrent Correa
Published: | Updated: 13/08/2018
Edited by: Top Doctors®

Ovarian cancer is the most common second among gynecologic cancers, endometrial cancer behind. In ovarian cancer, the most common is epithelial, which originates from the epithelial cells lining the surface of the ovary.

ovaries Specialists in Gynecology state that the most common symptoms of ovarian cancer include pelvic or abdominal pain, loss of appetite, urinary symptoms and bloating.

Currently there is no method that has shown efficacy in the diagnosis of ovarian cancer. Most cases are diagnosed at an early stage are due to gynecological examinations or when the patient is subjected to some type of abdominal surgery. In cases in which the ovarian cancer is diagnosed early, survival can be 90-95%.

 

Ovarian cancer: risk factors

The causes of ovarian cancer are unknown. However, there are some risk factors that cause some women have a higher risk of developing it.

A group of women who have an increased risk of ovarian cancer.

  • Genetic mutations: A woman has a mutation in BRCA1, BRCA2, MLH1, MSH2 and MSH6 genes have twice the risk of developing ovarian cancer.

 

Factors that reduce ovarian cancer

On the other hand, there are factors that have been shown to reduce the risk of ovarian cancer:

  • The use of oral contraceptives for a period of three years or more up to 50% reduces the risk
  • Tubal ligation
  • Hysterectomy
  • Having one or more children before age 30
  • Breastfeeding

 

Treatment of ovarian cancer

The main treatment for this cancer is surgery. Debulking surgery involves excision, commonly known as ablation, ovaries, uterus, tubes, appendix, pelvic and aortic lymph nodes. Also, all macroscopic disease that has in the abdomen. If the cancer has spread throughout the abdomen, resection is also performed in the spleen, small intestine and / or large, liver, pancreas and peritoneum and diaphragm. This type of surgery, if no residual tumor is not left, is associated with increased survival.

Chemotherapy is not able to penetrate large tumor masses. That is why so cytoreduction performed first, as it allows chemotherapy treatments more effective.

For this type of cancer, it is possible to administer chemotherapy intraperitoneally after debulking surgery. This involves placing a catheter into the abdomen, through which the treatment is injected.

*Translated with Google translator. We apologize for any imperfection

By Dr. Juan José Torrent Correa
Obstetrics & Gynecology

Founder of the JTI Surgical Oncology in Barcelona, ​​Dr. Torrent is an expert in minimally invasive oncological surgery (laparoscopy), a disciple of Professor Chapron, Hopital Cochin, of Paris. His professional activity began at the Institut Claudius Regaud (Toulouse), with Pr. Querleu, and, currently, he collaborates with the team of Dr. Françoise Quénet at the Institut du Cancer de Montpellier (ICM). His area of ​​specialization focuses on the surgical treatment of peritoneal carcinomatosis of ovarian origin and participates as a researcher in European clinical studies on peritoneal carcinomatosis, cytoreduction surgery and HIPEC.

*Translated with Google translator. We apologize for any imperfection

View Profile

Overall assessment of their patients


TOPDOCTORS utiliza cookies propias y de terceros para facilitar su experiencia como usuario de nuestra web y captar datos estadísticos mediante el análisis de sus datos de navegación. Si usted continúa con la navegación, entendemos que nos ofrece su consentimiento para el uso de cookies. Puede cambiar la configuración de cookies u obtener más información here.